Related Experiment Video
Updated: Jun 24, 2026
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Structure-based virtual screening of Src kinase inhibitors.
Kyungik Lee1, Jongwoo Kim, Ki-Woong Jeong
1Department of Chemistry, Konkuk University, Seoul 143-701, Republic of Korea.
Bioorganic & Medicinal Chemistry
|March 27, 2009
Summary
Researchers identified a novel compound, '43', as a potent and selective Src inhibitor. This compound demonstrated anti-proliferative effects on cancer cells and suppressed key downstream signaling pathways, showing promise for cancer therapy.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Cancer Research
Background:
- Src kinase is a critical regulator in tumor progression, influencing proliferation, neovascularization, and metastasis.
- Targeting Src offers a therapeutic strategy for various cancers.
Purpose of the Study:
- To identify and optimize novel, potent, and selective inhibitors of Src kinase.
- To evaluate the anti-cancer efficacy and mechanism of action of a lead compound.
Main Methods:
- Virtual screening and molecular docking were employed for hit identification and optimization.
- In vitro assays were used to determine inhibitory concentrations (IC50) against Src, EGFR, and VEGFR-2.
- Cell-based assays assessed anti-proliferative effects and downstream signaling inhibition in cancer cell lines.
Main Results:
- A novel compound, '43' ((S)-N-(4-(5-chlorobenzo[d][1,3]dioxol-4-ylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)pyrrolidine-2-carboxamide), was identified with an IC50 of 89 nM against Src.
- Compound 43 exhibited high selectivity for Src over EGFR and VEGFR-2 (>80-fold and >110-fold, respectively).
- Compound 43 demonstrated significant anti-proliferative activity against PC3 and A431 cancer cells and inhibited Src downstream signaling pathways.
Conclusions:
- Virtual screening effectively led to the discovery of potent Src inhibitors.
- Compound 43 represents a promising Src inhibitor candidate for further development in cancer therapy.
